Cybin D/B/A Helus Pharma (HELP)
NGM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Cybin D/B/A Helus Pharma
Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -24.6M | -28.9M | -41.2M | -47.9M |
| Net Income | -24.6M | -33.7M | -42.7M | -47.0M |
| Diluted EPS | $-1.10 | $-1.39 | $-1.00 | $nan |
Annual Financials
| Metric | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | ||||
| Operating Income | -51.5M | -78.8M | -143.1M | -142.6M |
| Net Income | -47.5M | -78.1M | -113.1M | -148.0M |
| Diluted EPS | $-9.88 | $-6.96 | $-5.59 | $nan |